Table 1 Baseline characteristics of overall patients
Variable | Overall cohort, N = 195 | DDR status |  | |
|---|---|---|---|---|
mut N = 30 (15.4%) | wt N = 165 (84.6%) | p value | ||
Age at diagnosis | Â | Â | Â | 0.35 |
 Median, years | 59.3 | 59.6 | 59.2 |  |
Sex, n (%) | Â | Â | Â | 0.569 |
 Male | 110 (56.4%) | 15 (50%) | 95 (57.6%) |  |
 Female | 85 (43.6%) | 15 (50%) | 70 (42.4%) |  |
Family history of cancer, n (%) | 31 (15.9%) | 7 (23.3%) | 24 (14.5%) | 0.347 |
 Pancreatic cancer | 5 (2.6%) | 1 (3.3%) | 4 (2.4%) |  |
 Any cancer | 26 (13.3%) | 6 (20%) | 20 (12.1%) |  |
Location of primary tumor, n (%) | Â | Â | Â | 0.253 |
 Head/uncinate | 123 (63.1%) | 15 (50%) | 108 (65.5%) |  |
 Body/tail | 47 (24.1%) | 10 (33.3%) | 37 (22.4%) |  |
 NA | 24 (12.3%) | 5 (16.7%) | 19 (11.5%) |  |
Surgery, n (%) | Â | Â | Â | 0.674 |
 R0 (Negative margin) | 109 (55.9%) | 16 (53.3%) | 93 (56.4%) |  |
 R1 (Positive margin) | 83 (42.6%) | 13 (43.3%) | 70 (42.4%) |  |
 NA | 3 (1.5%) | 1 (3.3%) | 2 (1.2%) |  |
Pathological T stage, n (%) | Â | Â | Â | 0.596 |
 T1 and T2 | 68 (34.9%) | 9 (30.0%) | 59 (35.8%) |  |
 T3 and T4 | 124 (63.6%) | 20 (66.7%) | 104 (63.0%) |  |
 NA | 3 (1.5%) | 1 (3.3%) | 2 (1.2%) |  |
Pathological N stage, n (%) | Â | Â | Â | 0.47 |
 N0 | 85 (43.6%) | 15 (50.0%) | 70 (42.4%) |  |
 N1/N2 | 107 (54.9%) | 14 (46.7%) | 93 (56.4%) |  |
 NA | 3 (1.5%) | 1 (3.3%) | 2 (1.2%) |  |
Metastasis, n (%) | Â | Â | Â | 0.632 |
 M0 | 132 (67.7%) | 19 (63.3%) | 112 (67.9%) |  |
 M1 | 60 (30.8%) | 10 (33.3%) | 50 (30.3%) |  |
 NA | 3 (1.5%) | 1 (3.3%) | 2 (1.2%) |  |
Stage, n (%) | Â | Â | Â | 0.950 |
 Limited stage | 72 (36.7%) | 11 (36.7%) | 61 (37.0%) |  |
 Advanced stage | 123 (62.8%) | 19 (63.3%) | 104 (63.0%) |  |
Perivascular invasion, n (%) | Â | Â | Â | 0.686 |
 Present | 40 (20.5%) | 6 (20.0%) | 34 (20.6%) |  |
 Absent | 152 (77.9%) | 23 (76.7%) | 129 (78.2%) |  |
 NA | 3 (1.5%) | 1 (3.3%) | 2 (1.2%) |  |
Perineural invasion, n (%) | Â | Â | Â | 0.68 |
 Present | 75 (38.5%) | 11 (36.7%) | 64 (38.8%) |  |
 Absent | 117 (60.0%) | 18 (60.0%) | 99 (60.0%) |  |
 NA | 3 (1.5%) | 1 (3.3%) | 2 (1.2%) |  |
CA 19–9, n (%) |  |  |  | 0.055 |
 Normal | 44 (22.6%) | 7 (23.3%) | 37 (22.4%) |  |
 Elevated | 145 (74.4%) | 20 (66.7%) | 125 (75.8%) |  |
 Unknown | 6 (3.1%) | 3 (10.0%) | 3 (1.8%) |  |
Surgery, n (%) | Â | Â | Â | 0.857 |
 Curative surgery | 109 (55.9%) | 16 (53.3%) | 93 (56.4%) |  |
 Unresectable cancer | 85 (43.6%) | 14 (46.7%) | 71 (43.0%) |  |
 NA | 1 (0.5%) | 0 (0.0%) | 1 (0.6%) |  |
Adjuvant radiotherap or chemotherapy, n (%) | Â | Â | Â | 0.094 |
 Yes | 84 (43.1%) | 15 (50%) | 69 (41.8%) |  |
 No | 44 (22.5%) | 7 (23.3%) | 37 (22.4%) |  |
 Unknown | 67 (34.4%) | 8 (26.7%) | 59 (35.8%) |  |